AKBA (Akebia Therapeutics) FFO


AKBA Akebia Therapeutics Inc AKBA
49 GF Score
Price $1.14
GF Value $1.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

AKBA
49GF Score
Akebia Therapeutics Inc AKBA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akebia Therapeutics (AKBA) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of $1.14 is trading 13% below its estimated GF Value™ of $1.31. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for AKBA:

  • FFO:
  • GF Value™: $1.31 vs. price of $1.14 (13% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
49GF Score

Get the complete analysis for AKBA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price
$1.31
GF Value